Information Journal Paper
APA:
Copy. (2018). Diallyl Disulfide inhibits breast cancer stem cell progression and glucose metabolism by targeting CD44/PKM2/AMPK signaling. CURRENT CANCER DRUG TARGETS, 18(6), 592-599. SID. https://sid.ir/paper/735677/en
Vancouver:
Copy. Diallyl Disulfide inhibits breast cancer stem cell progression and glucose metabolism by targeting CD44/PKM2/AMPK signaling. CURRENT CANCER DRUG TARGETS[Internet]. 2018;18(6):592-599. Available from: https://sid.ir/paper/735677/en
IEEE:
Copy, “Diallyl Disulfide inhibits breast cancer stem cell progression and glucose metabolism by targeting CD44/PKM2/AMPK signaling,” CURRENT CANCER DRUG TARGETS, vol. 18, no. 6, pp. 592–599, 2018, [Online]. Available: https://sid.ir/paper/735677/en